Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and JOHN CHARLES ARAUJO.
CHRISTOPHER J LOGOTHETIS
Connection Strength
2.091
JOHN CHARLES ARAUJO
  1. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 2010 Oct; 36(6):492-500.
    View in: PubMed
    Score: 0.371
  2. Targeting Src signaling in metastatic bone disease. Int J Cancer. 2009 Jan 01; 124(1):1-6.
    View in: PubMed
    Score: 0.342
  3. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol. 2020 02; 3(1):119-127.
    View in: PubMed
    Score: 0.175
  4. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1307-16.
    View in: PubMed
    Score: 0.120
  5. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30.
    View in: PubMed
    Score: 0.116
  6. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 01; 118(1):63-71.
    View in: PubMed
    Score: 0.102
  7. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther. 2009 Nov; 8(22):2153-9.
    View in: PubMed
    Score: 0.091
  8. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clin Cancer Res. 2024 Mar 15.
    View in: PubMed
    Score: 0.061
  9. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Na?ve Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 05 20; 41(15):2736-2746.
    View in: PubMed
    Score: 0.057
  10. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 2021 11; 40(44):6284-6298.
    View in: PubMed
    Score: 0.052
  11. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267.
    View in: PubMed
    Score: 0.052
  12. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946.
    View in: PubMed
    Score: 0.047
  13. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5.
    View in: PubMed
    Score: 0.047
  14. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa003.
    View in: PubMed
    Score: 0.046
  15. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75.
    View in: PubMed
    Score: 0.046
  16. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2019 02 10; 37(5):403-410.
    View in: PubMed
    Score: 0.043
  17. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589.
    View in: PubMed
    Score: 0.039
  18. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep. 2016 10 17; 6:35354.
    View in: PubMed
    Score: 0.037
  19. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924.
    View in: PubMed
    Score: 0.037
  20. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer. 2016 09 06; 16:721.
    View in: PubMed
    Score: 0.036
  21. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 05 10; 34(14):1652-9.
    View in: PubMed
    Score: 0.035
  22. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 01; 121(1):69-76.
    View in: PubMed
    Score: 0.032
  23. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15; 74(6):1651-60.
    View in: PubMed
    Score: 0.030
  24. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate. 2013 Jun; 73(9):979-85.
    View in: PubMed
    Score: 0.028
  25. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011 Nov 30; 3(111):111ra121.
    View in: PubMed
    Score: 0.026
  26. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011 Jun 01; 71(8):846-56.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.